Literature DB >> 32705269

Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Stella Baliou1, Anthony M Kyriakopoulos2, Demetrios A Spandidos3, Vassilios Zoumpourlis1.   

Abstract

For one century, <span class="Chemical">taurine is <span class="Chemical">considered as an end product of sulfur metabolism. In this review, we discuss the beneficial effect of taurine, its haloamines and taurine upregulated gene 1 (TUG1) long non‑coding RNA (lncRNA) in both cancer and inflammation. We outline how taurine or its haloamines (N‑Bromotaurine or N‑Chlorotaurine) can induce robust and efficient responses against inflammatory diseases, providing insight into their molecular mechanisms. We also provide information about the use of taurine as a therapeutic approach to cancer. Taurine can be combined with other chemotherapeutic drugs, not only mediating durable responses in various malignancies, but also circumventing the limitations met from chemotherapeutic drugs, thus improving the therapeutic outcome. Interestingly, the lncRNA TUG1 is regarded as a promising therapeutic approach, which can overcome acquired resistance of cancer cells to selected strategies. In this regard, we can translate basic knowledge about taurine and its TUG1 lncRNA into potential therapeutic options directed against specific oncogenic signaling targets, thereby bridging the gap between bench and bedside.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32705269      PMCID: PMC7384849          DOI: 10.3892/ijo.2020.5100

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  424 in total

1.  Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.

Authors:  Vandana Megaraj; Takashi Iida; Paiboon Jungsuwadee; Alan F Hofmann; Mary Vore
Journal:  Drug Metab Dispos       Date:  2010-07-19       Impact factor: 3.922

Review 2.  Role of taurine in spinal cord injury.

Authors:  R C Gupta; Y Seki; J Yosida
Journal:  Curr Neurovasc Res       Date:  2006-08       Impact factor: 1.990

3.  The antioxidant, taurine reduced lipopolysaccharide (LPS)-induced generation of ROS, and activation of MAPKs and Bax in cultured pneumocytes.

Authors:  Seol-Hee Jeon; Mun-Young Lee; Md Mizanur Rahman; Shang-Jin Kim; Gi-Beum Kim; Sang-Youel Park; Chul-Un Hong; Sung-Zoo Kim; Jin-Shang Kim; Hyung-Sub Kang
Journal:  Pulm Pharmacol Ther       Date:  2009-08-06       Impact factor: 3.410

4.  Taurine chloramine inhibits proliferation of rheumatoid arthritis synoviocytes by triggering a p53-dependent pathway.

Authors:  E Kontny; W Rudnicka; M Chorazy-Massalska; J Marcinkiewicz; W Maśliński
Journal:  Inflamm Res       Date:  2006-10       Impact factor: 4.575

5.  Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB.

Authors:  Ming Sun; Yumei Zhao; Yi Gu; Chao Xu
Journal:  Amino Acids       Date:  2011-03-16       Impact factor: 3.520

6.  Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats.

Authors:  Sang K Kim; Young C Kim
Journal:  Food Chem Toxicol       Date:  2002-04       Impact factor: 6.023

7.  Chlorination of endogenous amines by isolated neutrophils. Ammonia-dependent bactericidal, cytotoxic, and cytolytic activities of the chloramines.

Authors:  M B Grisham; M M Jefferson; D F Melton; E L Thomas
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

8.  Protection by taurine against INOS-dependent DNA damage in heavily exercised skeletal muscle by inhibition of the NF-κB signaling pathway.

Authors:  Hiromichi Sugiura; Shinya Okita; Toshihiro Kato; Toru Naka; Shosuke Kawanishi; Shiho Ohnishi; Yoshiharu Oshida; Ning Ma
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment.

Authors:  Keisuke Katsushima; Atsushi Natsume; Fumiharu Ohka; Keiko Shinjo; Akira Hatanaka; Norihisa Ichimura; Shinya Sato; Satoru Takahashi; Hiroshi Kimura; Yasushi Totoki; Tatsuhiro Shibata; Mitsuru Naito; Hyun Jin Kim; Kanjiro Miyata; Kazunori Kataoka; Yutaka Kondo
Journal:  Nat Commun       Date:  2016-12-06       Impact factor: 14.919

10.  LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells.

Authors:  Xiao-Bo Zhao; Guo-Sheng Ren
Journal:  J Breast Cancer       Date:  2016-12-23       Impact factor: 3.588

View more
  7 in total

Review 1.  Current Opinion on the Therapeutic Capacity of Taurine-Containing Halogen Derivatives in Infectious and Inflammatory Diseases.

Authors:  Janusz Marcinkiewicz; Markus Nagl; Anthony Kyriakopoulos; Maria Walczewska; Magdalena Skóra; Paulina Skalska
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics.

Authors:  Zhitao Ni; Shaolin Xu; Zheng Yu; Zhongjiang Ye; Rongqi Li; Chuang Chen; Jianhui Yang; Huamin Liu; Ziye Zhou; Xiuhua Zhang
Journal:  Invest New Drugs       Date:  2022-09-05       Impact factor: 3.651

3.  Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.

Authors:  Juntao Zhuang; Xiao Yang; Qi Zheng; Kai Li; Lingkai Cai; Hao Yu; Jiancheng Lv; Kexin Bai; Qiang Cao; Pengchao Li; Haiwei Yang; Junsong Wang; Qiang Lu
Journal:  Metabolites       Date:  2022-06-17

4.  Bromamine T, a stable active bromine compound, prevents the LPS‑induced inflammatory response.

Authors:  Stella Baliou; Michael Sofopoulos; Maria Goulielmaki; Demetrios A Spandidos; Petros Ioannou; Anthony M Kyriakopoulos; Vassilios Zoumpourlis
Journal:  Int J Mol Med       Date:  2021-02-04       Impact factor: 4.101

5.  Metabolomics based plasma biomarkers for diagnosis of oral squamous cell carcinoma and oral erosive lichen planus.

Authors:  Xibo Li; Liwei Liu; Na Li; Qingquan Jia; Xiaoshuang Wang; Lihua Zuo; Jianglan Long; Peng Xue; Zhi Sun; Hongyu Zhao
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

6.  Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice.

Authors:  James D Barnett; Jiefu Jin; Marie-France Penet; Hisataka Kobayashi; Zaver M Bhujwalla
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

7.  Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics.

Authors:  Mohd Yousuf; Anas Shamsi; Taj Mohammad; Naved Azum; Sulaiman Y M Alfaifi; Abdullah M Asiri; Abdelbaset Mohamed Elasbali; Asimul Islam; Md Imtaiyaz Hassan; Qazi Mohd Rizwanul Haque
Journal:  ACS Omega       Date:  2022-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.